TOTAL VOLUME:

$134.2b

24H VOL:

$126,324,530

24H TRANSACTIONS:

2,388,728,490

OPEN INTEREST:

$1,434,646,834

406,019

Markets across

30,401

events

MATCHED EVENTS:

2,689

PLATFORM COVERAGE:

5

Polymarket:

39%

VS.

Kalshi:

61%

BETA
Dashboards
Tour
All
Companies
Will Eli Lilly (LLY) Q2 Mounjaro sales be above __?
polymarket

Will Eli Lilly (LLY) Q2 Mounjaro sales be above __?

Volume:
$1,097

$9.75B

 - Polymarket

$9.75B - Polymarket

1W

News

Positive

Negative

Neutral

Hover marker for details

Vol.

·

Resolved Aug 5, 2026

Closed: Aug 5, 8:48 AM EST

polymarket

Polymarket

View
Outcome
Trade
Chance %
Price
Spread
Liquidity
Volume
24h
7d
Open Interest
Ends in
Result
polymarket

$9.75B

View
100%
Yes 100¢No 0¢
0.1¢
N/A
$336
N/A
N/A
N/A
Settled
Yes
polymarket

$7.5B

100%
Yes 100¢No 0¢
0.1¢
N/A
$190
N/A
N/A
N/A
Settled
Yes
polymarket

$8.25B

100%
Yes 100¢No 0¢
1¢
N/A
$135
N/A
N/A
N/A
Settled
Yes
polymarket

$9B

100%
Yes 100¢No 0¢
1¢
N/A
$119
N/A
N/A
N/A
Settled
Yes
polymarket

$10.5B

0%
Yes 0¢No 100¢
—
N/A
$317
N/A
N/A
N/A
Settled
No
Total markets: 5

Description

This market will resolve to "Yes" if Eli Lilly's Mounjaro total sales for the upcoming second fiscal quarter, as reported in its official company earnings materials, are above the listed amount. Otherwise, this market will resolve to "No". The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered. If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to "No". If the specified company does not release quarterly earnings materials for the specified quarter by September 30, 2026, 11:59 PM ET, this market will resolve to "No". If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market. The resolution source for this market is the specified company's official company earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used. Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.

Polymarket

This market will resolve to "Yes" if Eli Lilly's Mounjaro total sales for the upcoming second fiscal quarter, as reported in its official company earnings materials, are above the listed amount. Otherwise, this market will resolve to "No". The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered. If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to "No". If the specified company does not release quarterly earnings materials for the specified quarter by September 30, 2026, 11:59 PM ET, this market will resolve to "No". If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market. The resolution source for this market is the specified company's official company earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used. Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.

Frequently asked questions

This market resolves around Aug 5, 2026, with the outcome confirmed once the event is verifiable from credible public reporting. The final sales figure for Eli Lilly’s Q2 will be compared against the market’s target threshold, and the market will settle based on that official release. Until then, any major sales updates, earnings previews, or regulatory news could influence trader positions.

Key signals include preliminary sales data leaks, management commentary during investor calls, changes in demand forecasts, and any regulatory updates affecting Mounjaro’s availability. Additionally, broader market trends, such as investor sentiment toward biotech stocks or macroeconomic factors impacting pharmaceutical spending, could shift this market. As Aug 5, 2026 approaches, any official guidance or early data releases will likely cause notable price swings.